By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting from Rostock, Germany, by NewsRx journalists, research stated, "Due to the fundamental progress in elucidating the molecular mechanisms of human diseases and the arrival of the post-genomic era, increasing numbers of therapeutic genes and cellular targets are available for gene therapy. Meanwhile, the most important challenge is to develop gene delivery vectors with high efficiency through target cell selectivity, in particular under in situ conditions."
The news correspondents obtained a quote from the research from the University of Rostock, "The most widely used vector system to transduce cells is based on adenovirus (Ad). Recent endeavors in the development of selective Ad vectors that target cells or tissues of interest and spare the alteration of all others have focused on the modification of the virus broad natural tropism. A popular way of Ad targeting is achieved by directing the vector towards distinct cellular receptors. Redirecting can be accomplished by linking custom-made peptides with specific affinity to cellular surface proteins via genetic integration, chemical coupling or bridging with dual-specific adapter molecules. Ideally, targeted vectors are incapable of entering cells via their native receptors. Such altered vectors offer new opportunities to delineate functional genomics in a natural environment and may enable efficient systemic therapeutic approaches."
According to the news reporters, the research concluded: "This review provides a summary of current state-of-the-art techniques to specifically target adenovirus-based gene delivery vectors."
For more information on this research see: Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer. Viruses, 2014;6(4):1540-63 (see also Biotechnology).
Our news journalists report that additional information may be obtained by contacting J. Reetz, Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Schillingallee 69, Rostock 18057, Germany. Additional authors for this research include O. Herchenroder and B.M Putzer.
Keywords for this news article include: Biotechnology, Europe, Rostock, Germany, Genetics, Oncology, Peptides, Proteins, Proteomics, Therapeutics, Bioengineering, Cancer Gene Therapy.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC